Taltz prior authorization guide: IL-17 documentation, biologic step therapy, indication-specific PA, and renewal evidence

Taltz (ixekizumab, Eli Lilly) is a humanized interleukin-17A antagonist approved for four indications: moderate-to-severe plaque psoriasis (PsO, age 6+), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. While Taltz is a preferred IL-17 inhibitor on the Express Scripts 2026 National Preferred Formulary, it faces significant access barriers on UHC (where it is excluded from coverage for the majority of benefits) and requires step therapy on most major plans.

This guide covers indication-specific PA criteria, biologic step-therapy sequencing, documentation requirements, and Lilly support programs for access teams navigating ixekizumab coverage.

Short answer

Payer positioning: a divided landscape

Taltz occupies an unusual position in the IL-17 class — preferred on Express Scripts but excluded on UHC commercial. This creates radically different access experiences depending on the patient's payer:

Indication-specific PA requirements

Plaque psoriasis (PsO)

PsO is the highest-volume Taltz indication and has the most demanding step-therapy requirements, particularly on UHC:

UHC commercial (excluded — requires exception):

1. Diagnosis of chronic moderate-to-severe plaque psoriasis, age 6+
2. Greater than or equal to 3% BSA involvement, palmoplantar, facial, genital involvement, or severe scalp psoriasis
3. Failure of one topical therapy (corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors)
4. Failure of one conventional systemic therapy or phototherapy (methotrexate, cyclosporine, acitretin, PUVA, UVB)
5. Failure of one prior biologic DMARD for psoriasis (adalimumab, Cimzia, Otezla, Skyrizi, ustekinumab, Tremfya, Enbrel)
6. Failure of three preferred products: one preferred adalimumab product, Cimzia, Cosentyx, Enbrel, Skyrizi, Sotyktu, one preferred ustekinumab product, and Tremfya — the patient must have failed at least three from this list
7. Failure of Bimzelx if applicable

Cigna (PA with step therapy):

1. Diagnosis of moderate-to-severe PsO, age 6+
2. Inadequate response, intolerance, or contraindication to either conventional systemic therapy or phototherapy
3. Must try preferred products first; Taltz requires prior failure of preferred alternatives

FEP Blue:

1. Age 6+, inadequate response to conventional systemic therapy or phototherapy
2. Must try preferred products per Appendix 2 unless valid medical exception exists
3. Quantity limit: 18 units (80 mg) per fill for loading dose period, then 3 units per 28 days

Medicaid (NH RI example):

1. Prescribed by or in consultation with a dermatologist or rheumatologist
2. At least 10% BSA affected OR crucial body areas involved
3. Minimum 3-month trial failure of methotrexate, cyclosporine, or acitretin — or clinically significant adverse effects
4. Initial authorization for 6 months; continuation for 12 months

Psoriatic arthritis (PsA)

PsA step therapy is less demanding than PsO but still requires biologic sequencing:

UHC commercial:

1. Diagnosis of active PsA
2. Failure of methotrexate at maximally indicated dose (unless contraindicated), OR prior treatment with a systemic targeted immunomodulator for PsA
3. Failure of preferred biologics: one preferred adalimumab product, Cimzia, Cosentyx, Enbrel, Skyrizi, one preferred ustekinumab product, Tremfya — at least three from this list

Cigna:

1. Diagnosis of active PsA
2. Failure of at least one conventional DMARD (methotrexate, sulfasalazine, leflunomide) or prior biologic use for PsA
3. Must try preferred products before Taltz

Ankylosing spondylitis (AS)

Typical PA pathway across payers:

1. Diagnosis of active AS by a rheumatologist
2. Failure of at least two NSAIDs over a minimum 4-week total duration
3. Biologic positioning: TNF inhibitors or IL-17 inhibitors are recommended as initial biologic therapy per ACR/SPARTAN guidelines
4. Some plans require TNF-inhibitor failure before IL-17 inhibitors

Western Health Advantage specifies: patients must have tried a total of two TNF inhibitors before accessing Taltz for AS, and patients should not be made to try a third TNF inhibitor.

Non-radiographic axial spondyloarthritis (nr-axSpA)

Typical pathway:

1. Diagnosis of active nr-axSpA with objective signs of inflammation (elevated CRP and/or MRI evidence of sacroiliitis)
2. Failure of at least two NSAIDs
3. Most plans require at least one TNF-inhibitor failure before an IL-17 inhibitor for nr-axSpA. Western Health Advantage requires inadequate response or intolerance to one or more TNF inhibitors.

Reauthorization criteria

Across UHC, Cigna, FEP Blue, and Medicaid plans, Taltz reauthorization follows a consistent pattern:

1. Duration: initial approvals range from 6 months (some Medicaid plans) to 12 months (commercial)
2. Clinical response documentation: positive clinical response evidenced by:
   • PsO: reduction in BSA, improvement in PASI score, improvement in itching, redness, scaling
   • PsA: improvement in joint counts, inflammatory markers, functional status
   • AS/nr-axSpA: improvement in BASDAI score, CRP, pain, morning stiffness, functional measures
3. IBD monitoring: prescriber must agree to monitor for onset or exacerbation of Crohn's disease or ulcerative colitis and discontinue if necessary
4. No concurrent targeted immunomodulators: Taltz must not be used in combination with other biologic DMARDs or targeted synthetic DMARDs
5. No concurrent live vaccines

Billing and coding

Most Taltz prescriptions are dispensed through specialty pharmacies on the pharmacy benefit and do not require J-code billing. Medical benefit billing applies when the SC injection is administered in-office.

Lilly support services

Taltz Savings Card

• Commercially insured patients with a plan that covers Taltz: $5 per month
• Commercially insured patients whose plan does not cover Taltz: $25 per month
• Not valid for Medicare, Medicaid, TRICARE, or government programs
• Activate by texting "TALTZ" to 85099

Lilly Support Services for Taltz

• Phone: 1-800-LILLYRX (1-800-545-5979)
• Hours: Monday–Friday, 8 AM–10 PM ET
• Services: benefits investigation, PA assistance, specialty pharmacy coordination, appeal support

Enhanced Specialty Pharmacy Partners

If a PA is denied, Lilly can route the prescription through enhanced specialty pharmacy partners for a "faster and smoother start experience," per the Lilly PA Resource Guide.

Step Therapy Protection Information

Lilly provides resources on step therapy legislation, exception request forms, and additional state-specific protections that may help patients bypass step-therapy requirements where state law allows.

Documentation checklist for PA submission

1. ICD-10 code: L40.0 (PsO), M07.0–M07.3 (PsA), M45.x (AS), or M46.8x (nr-axSpA)
2. Diagnosis confirmation: specialist attestation (dermatologist for PsO, rheumatologist for PsA/AS/nr-axSpA)
3. Disease severity documentation:
   • PsO: BSA percentage, PASI score, affected body areas
   • PsA: joint counts, tender/swollen joint count, dactylitis, enthesitis
   • AS/nr-axSpA: BASDAI score, CRP, MRI findings
4. TB screening: negative TB test (skin test or IGRA) within 12 months prior to initiation
5. Prior treatment history: drug name, dose, start/stop dates, duration, and reason for discontinuation for each prior therapy, including:
   • Topical therapies (PsO)
   • Conventional systemic agents (methotrexate, cyclosporine, acitretin)
   • Phototherapy history
   • NSAID trials (AS, nr-axSpA)
   • Prior biologics: document each biologic by name, dates, and reason for failure
6. Medical necessity letter: explain why Taltz is appropriate over preferred alternatives, citing prior failures, contraindications, or disease-specific considerations (e.g., IBD history favoring IL-17 over TNF inhibitors)

Key takeaways for access teams

• Taltz access is payer-dependent: preferred on Express Scripts but excluded on UHC commercial. Confirm formulary status before prescribing.
• UHC requires failure of 3+ preferred biologics for PsO: this is one of the most demanding step-therapy requirements in dermatology. Prepare comprehensive prior-treatment documentation.
• Express Scripts preference means first-line IL-17 access for millions of covered lives — leverage this when Taltz is clinically appropriate.
• nr-axSpA typically requires TNF-inhibitor failure first: most plans treat IL-17 inhibitors as second-line biologics for axial disease.
• Reauthorization needs IBD monitoring attestation: IL-17 inhibition can exacerbate Crohn's disease and ulcerative colitis. Document that the prescriber is monitoring for IBD onset or flare.
• Lilly's $5/month savings card for covered commercial patients and $25/month for non-covered plans provides significant cost relief at point of access.

Sources

• Eli Lilly. Taltz (ixekizumab) Prescribing Information. taltz.lilly.com
• FDA. Taltz (ixekizumab) Prescribing Information. BLA 125521. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125521s028lbl.pdf
• FDA. Drugs@FDA: Taltz (ixekizumab). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
• Eli Lilly. Prior Authorization Resource Guide. CMAT-01269 10/2025. taltz.lilly.com/assets/pdf/pp-ix-us-6595-prior-authorization-resource-guide.pdf
• UnitedHealthcare. Taltz (ixekizumab) Prior Authorization/Medical Necessity. Program 2025 P 2104-19. Effective 06/01/2025. uhcprovider.com
• UnitedHealthcare. Taltz (ixekizumab) Step Therapy Program. Program 2025 P 3073-19. uhcprovider.com
• Cigna. Inflammatory Conditions – Taltz Prior Authorization Policy. IP0688. Effective 01/01/2026. static.cigna.com
• Mass General Brigham Health Plan. Taltz (ixekizumab) PA Policy. Effective 05/01/2026. resources.massgeneralbrighamhealthplan.org
• FEP Blue. Taltz (ixekizumab) Coverage Policy. 5.90.018. Effective January 1, 2026. fepblue.org
• NH RI Medicaid. Specialty Guideline Management: Taltz (ixekizumab). nhpri.org
• Western Health Advantage. Taltz (ixekizumab) PA Criteria. westernhealth.com
• Blue Cross Blue Shield of Florida. Ixekizumab (Taltz) Medical Coverage Guideline. mcgs.bcbsfl.com
• Express Scripts. 2026 National Preferred Formulary. express-scripts.com/pdf/formulary/NPE1702_204612.pdf
• CounterForce Health. How to Get Taltz Covered by UHC: PA Guide with Appeals. counterforcehealth.org
• PrescriberPoint. Taltz (ixekizumab) Dosing, PA Forms & Info. prescriberpoint.com/therapies/taltz-ac96658